Predicting Ischemic and Bleeding Risk in Patients after PCI on DAPT: An Individualized Patient Centered Machine Learning Model

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - Abbott; Abiomed; Alleviant Medical; Amgen; AM-Pharma; Arena; AstraZeneca; Biosensors; Biotronik; Boston Scientific Corporation; Bristol-Myers Squibb; CardiaWave; CeloNova; Chiesi; Concept Medical; CytoSorbents; Daiichi-Sankyo/Elil Lilly and Company; Element Science; Faraday Pharmaceuticals; Humacyte; Idorsia Pharmaceuticals; Janssen; Medtronic; Novartis; OrbusNeich; Penumbra; PhaseBio; Philips; Pi-Cardia; PLx Pharma; Protembis; RenalPro; RM Global; Shockwave; Vivasure; Zoll; Magenta; Mediasphere; Medtelligence
• Consultant Fee/Honoraria/Speaker's Bureau - Novartis; Ionis Pharmaceuticals; Vectura; WebMD; AstraZenca; J-CalC; Novo Nordisk
• Equity/Stock(s)/Options - Applied Therapeutics; Elixir Medical; Stel